Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
| Status: | Terminated |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2011 |
| End Date: | March 2014 |
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety,
tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension
patients.
tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension
patients.
Inclusion Criteria:
- Patients who completed in CQTI571A2102 clinical trial including all Study Completion
assessments at the end of study visit met the eligibility criteria for that study and
did not meet withdrawal criteria for safety reasons during study conduct
Exclusion Criteria:
- Patients with left ventricular ejection fraction (LVEF) < 45%
- Patients with thrombocytopenia, platelet count < 50 x109/L (50 x 103/µL).
- Patients with uncontrolled systemic arterial hypertension, systolic pressure > 160
mmHg or diastolic pressure > 90 mmHg.
- Patients with a QTcF > 450 ms for males and > 470 ms for females in the absence of
right bundle branch block.
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials